Skip to main content
Top

Open Access 08-06-2024 | Tirzepatide | Meta- Analysis

Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial

Authors: Wenhui Qin, Jun Yang, Ying Ni, Chao Deng, Qinjuan Ruan, Jun Ruan, Peng Zhou, Kai Duan

Published in: Endocrine

Login to get access

Abstract

Aim

Tirzepatide, a newly developed dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has received approval for treating type 2 diabetes (T2D) and is currently being studied for its potential in long-term weight control. We aim to explore the safety and efficacy of once-weekly subcutaneous tirzepatide for weight loss in T2D or obese patients.

Methods

A comprehensive search was performed on various databases including PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception up to April 29, 2024, to identify randomized controlled trials (RCTs) that assessed the efficacy of once-weekly tirzepatide compared to a placebo in adults with or without T2D. The mean difference (MD) and risk ratio (RR) were calculated for continuous and dichotomous outcomes, respectively. The risk of bias was evaluated using the RoB-2 tool (Cochrane), while the statistical analysis was conducted utilizing RevMan 5.4.1 software.

Results

Seven RCTs comprising 4795 individuals ranging from 12 to 72 weeks were identified. Compared to the placebo group, tirzepatide at doses of 5, 10, and 15 mg demonstrated significant dose-dependent weight loss. The mean difference (MD) in the percentage change in body weight (BW) was −8.07% (95% CI −11.01, −5.13; p < 0.00001), −10.79% (95% CI −13.86, −7.71; p < 0.00001), and −11.83% (95% CI −14.52, −9.14; p < 0.00001), respectively. Additionally, the MD in the absolute change in BW was −7.5 kg (95% CI −10.9, −4.1; p < 0.0001), −11.0 kg (95% CI −16.9, −5.2; p = 0.0002), and −11.5 kg (95% CI −16.2, −6.7; p < 0.00001), for the 5, 10, and 15 mg doses, respectively. All three doses of tirzepatide also significantly reduced body mass index and waist circumference. Furthermore, it led to a greater percentage of patients experiencing weight loss exceeding 5, 10, 15, 20, and 25%. Moreover, tirzepatide showed great success in reducing blood pressure, blood sugar levels, and lipid profiles. In terms of safety, gastrointestinal side effects were the most frequently reported adverse events in all three doses of tirzepatide groups, which were generally mild-to-moderate and transient.

Conclusion

Tirzepatide treatment could lead to remarkable and sustained weight loss that is well-tolerated and safe, representing a novel and valuable therapeutic strategy for long-term weight management.
Appendix
Available only for authorised users
Literature
3.
go back to reference L.M. Wang, B. Zhou, Z.P. Zhao et al. Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004–18. Lancet 398(10294), 53–63 (2021)CrossRefPubMed L.M. Wang, B. Zhou, Z.P. Zhao et al. Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004–18. Lancet 398(10294), 53–63 (2021)CrossRefPubMed
8.
go back to reference Q. Zeng, N.S. Li, X.F. Pan et al. Clinical management and treatment of obesity in China. Lancet Diab. Endocrinol. 9(6), 393–405 (2021)CrossRef Q. Zeng, N.S. Li, X.F. Pan et al. Clinical management and treatment of obesity in China. Lancet Diab. Endocrinol. 9(6), 393–405 (2021)CrossRef
11.
go back to reference J.P. Frias, M.A. Nauck, J. Van et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet (Lond., Engl.) 392(10160), 2180–2193 (2018). https://doi.org/10.1016/S0140-6736(18)32260-8CrossRef J.P. Frias, M.A. Nauck, J. Van et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet (Lond., Engl.) 392(10160), 2180–2193 (2018). https://​doi.​org/​10.​1016/​S0140-6736(18)32260-8CrossRef
16.
go back to reference J.P. Frias, M.A. Nauck, J. Van et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens[J]. Diab. Obes. Metab. 22(6), 938–946 (2020). https://doi.org/10.1111/dom.13979CrossRef J.P. Frias, M.A. Nauck, J. Van et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens[J]. Diab. Obes. Metab. 22(6), 938–946 (2020). https://​doi.​org/​10.​1111/​dom.​13979CrossRef
17.
go back to reference T. Heise, A. Mari, J.H. DeVries et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diab. Endocrinol. 10(6), 418–429 (2022). https://doi.org/10.1016/S2213-8587(22)00085-7CrossRef T. Heise, A. Mari, J.H. DeVries et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diab. Endocrinol. 10(6), 418–429 (2022). https://​doi.​org/​10.​1016/​S2213-8587(22)00085-7CrossRef
20.
27.
go back to reference J. Wilding, R. Batterham, S. Calanna et al. Once-weekly semaglutide in adults with overweight or obesity. : N. Engl. J. Med. 384, 989–1002 (2021)CrossRefPubMed J. Wilding, R. Batterham, S. Calanna et al. Once-weekly semaglutide in adults with overweight or obesity. : N. Engl. J. Med. 384, 989–1002 (2021)CrossRefPubMed
39.
go back to reference A. Gastaldelli, K. Cusi, L. Fernández Landó et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diab. Endocrinol. 10(6), 393–406 (2022). https://doi.org/10.1016/s2213-8587(22)00070-5CrossRef A. Gastaldelli, K. Cusi, L. Fernández Landó et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diab. Endocrinol. 10(6), 393–406 (2022). https://​doi.​org/​10.​1016/​s2213-8587(22)00070-5CrossRef
44.
go back to reference H. Patel, K. Khunti, H.W. Rodbard et al. Tirzepatide-induced weight loss in type 2 diabetes is independent of nausea, vomiting, or diarrhoea. Diabetologia 65(abstr 568), 290–91 (2022). H. Patel, K. Khunti, H.W. Rodbard et al. Tirzepatide-induced weight loss in type 2 diabetes is independent of nausea, vomiting, or diarrhoea. Diabetologia 65(abstr 568), 290–91 (2022).
45.
go back to reference S. Wharton, S. Calanna, M. Davies et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diab. Obes. Metab. 24(1), 94–105 (2022). https://doi.org/10.1111/dom.14551CrossRef S. Wharton, S. Calanna, M. Davies et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diab. Obes. Metab. 24(1), 94–105 (2022). https://​doi.​org/​10.​1111/​dom.​14551CrossRef
47.
go back to reference J. Tillner, M.G. Posch, F. Wagner et al. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials. Diab. Obes. Metab. 21(1), 120–128 (2019). https://doi.org/10.1111/dom.13494CrossRef J. Tillner, M.G. Posch, F. Wagner et al. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials. Diab. Obes. Metab. 21(1), 120–128 (2019). https://​doi.​org/​10.​1111/​dom.​13494CrossRef
48.
Metadata
Title
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial
Authors
Wenhui Qin
Jun Yang
Ying Ni
Chao Deng
Qinjuan Ruan
Jun Ruan
Peng Zhou
Kai Duan
Publication date
08-06-2024
Publisher
Springer US
Published in
Endocrine
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-024-03896-z
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare